MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00089076|
Recruitment Status : Terminated
First Posted : August 5, 2004
Results First Posted : October 19, 2012
Last Update Posted : May 30, 2014
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Adult Grade III Lymphomatoid Granulomatosis B-cell Chronic Lymphocytic Leukemia Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Refractory Hairy Cell Leukemia Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Testicular Lymphoma Waldenström Macroglobulinemia||Biological: ipilimumab Other: laboratory biomarker analysis||Phase 1 Phase 2|
I. To characterize the safety profile of MDX-010 (ipilimumab) monoclonal antibody and identify a tolerable immunologically active dose level in B cell lymphoma patients.
II. To evaluate the clinical response rate in B cell lymphoma patients treated with MDX-010.
I. To evaluate the phenotype and function of memory T cells before and after treatment with MDX-010 by:
- Quantitation and phenotypic characterization of peripheral blood and tumor infiltrating T-cells, including cluster of differentiation (CD)4+CD25+ regulatory T cells.
- Measurement of tumor-specific T cells in peripheral blood lymphocytes.
- Measuring proliferation of memory T cells in response to recall antigens (tetanus toxoid and keyhole limpet hemocyanin [KLH]).
II. Measurement of anti-tumor antibodies in serum pre- and post-therapy. III. To evaluate the time to progression. IV. To evaluate the duration of response to treatment with MDX-010.
OUTLINE: This is a multicenter, open-label, phase I, dose-escalation study followed by a phase II study. Patients are grouped according to prior treatment with a vaccine therapy for lymphoma (yes vs no).
PHASE I: Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
PHASE II: Patients receive MDX-010 as in phase I at the MTD.
Patients are followed at 1 and 4 months and then every 6 months for up to 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||October 2009|
Experimental: Treatment (ipilimumab)
PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
PHASE II: Patients receive MDX-010 as in phase I at the MTD.
Other: laboratory biomarker analysis
- Number of Overall Confirmed Responses(Complete Response or Partial Response) [ Time Frame: From registration to month 7 ]Confirmed response is at least a 50% decrease in the sum of the products of the greatest diameters (SPD) of the six largest dominant nodes or nodal masses and no increase in the size of other nodes, liver, or spleen and splenic and hepatic nodules must regress by at least 50% in the SPD and no new sites of disease.
- Time to Progression (Phase 2) [ Time Frame: From registration to progression (up to 2 years) ]The time to progression is defined as the time from registration to the time of progression. Those who die will be considered to have had disease progression unless documented evidence clearly indicates no progression has occurred. The distribution of time to progression will be estimated using the method of Kaplan-Meier.
- Overall Survival (Phase 2) [ Time Frame: From registration to death (up to 2 years) ]The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier.
- Duration of Response (Phase 2) [ Time Frame: From response to progression (up to 2 years) ]Duration of response will be calculated from the documentation of confirmed response until the date of progression in the subset of patients who respond.
- Mean Change in % of CD3+CD4+ for Marker HLA-DR+ [ Time Frame: Before treatment to 1 month after therapy initiation ]Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy
- Mean Change in % of CD3+CD4- for Marker HLA-DR+ [ Time Frame: Before treatment to 1 month after therapy initiation ]Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy
- Mean Change in % of CD3+CD4+ for Marker CD45RO+ [ Time Frame: Before treatment to 1 month after therapy initiation ]Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy
- Mean Change in % of CD3+CD4- for the Marker CD45RO+ [ Time Frame: Before treatment to 1 month after therapy initiation ]Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologic proof of recurring or residual follicular B-cell non-Hodgkin's lymphoma (grade I or II), by Revised European American Lymphoma Classification (REAL) or World Health Organization (WHO) classifications which has relapsed or persisted after 3 or fewer conventional therapies, including chemotherapy or monoclonal antibody therapy; note: all patients with previously treated B-cell lymphomas of any histology with the exception of small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL) are eligible
- Tumor measurable by computed tomography (CT) scans (at least one pathologic node measuring 2.0 x 2.0 cm, or 2 nodes measuring > 1.5 x 1.5 cm after collection of tumor for immunologic analyses)
- At least one prior treatment regimen but no more than 3 prior chemotherapy regimens; patients previously treated with monoclonal antibodies or radiotherapy to a single site will be eligible; these therapies will be considered prior treatment regimens but will not be considered as prior chemotherapy; tumor vaccines will not be counted as prior therapies, as all such agents are investigational
- Absolute neutrophil count (ANC) >= 1000/uL
- Platelets (PLT) >= 75,000/uL
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) =< 3 x upper limit or normal (ULN)
- Creatinine =< 1.5 x ULN
- Hemoglobin >= 8 g/dL
- Ability to provide informed consent
- Willingness to return to the Mayo Clinic Rochester or the University of California, Los Angeles for follow up
- Life expectancy >= 24 weeks
- Willingness to provide all biologic specimens as required by the protocol
- Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, 3, or 4
- Any uncontrolled infection, hepatitis C virus (HCV)+ (unless HCV ribonucleic acid [RNA]-negative by polymerase chain reaction [PCR]) or hepatitis B surface antigen (HBsAg)+, or human immunodeficiency virus (HIV) positive patients or patients with known immune deficiency states
- Previous MDX-010 therapy regardless of interval since last treatment
- Prior treatment with fludarabine or 2-chlorodeoxyadenosine =< 12 months prior to registration
- Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment
- New York Heart Association classification III or IV or a history of angina pectoris requiring active treatment
- Clinical evidence of central nervous system involvement by lymphoma
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], or abstinence, etc.)
- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)
- Diagnosis of small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL)
- Any requirement for concurrent steroid therapy, including use of inhaled steroids for asthma
- History of autoimmune disease requiring systemic therapy with immunosuppressive drugs, including but not limited to rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, or psoriasis
- Antinuclear antibody (ANA) titer or rheumatoid factor titer > 3x institutional ULN
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00089076
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Stephen Ansell||Mayo Clinic|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
NCI-2012-02784 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
MC0312 ( Other Identifier: Mayo Clinic )
6359 ( Other Identifier: CTEP )
P30CA015083 ( U.S. NIH Grant/Contract )
U01CA069912 ( U.S. NIH Grant/Contract )
|First Posted:||August 5, 2004 Key Record Dates|
|Results First Posted:||October 19, 2012|
|Last Update Posted:||May 30, 2014|
|Last Verified:||December 2012|
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell, Marginal Zone
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Immunoblastic
Leukemia, Hairy Cell
Lymphoma, Extranodal NK-T-Cell
Neoplasms by Histologic Type
Immune System Diseases